Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
MDS (Myelodysplastic Syndrome): early-phase trial registry
6 of 7 indexed MDS (Myelodysplastic Syndrome) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count
MDS (Myelodysplastic Syndrome): 7 US clinical trials tracked, 6 recruiting.
MDS (Myelodysplastic Syndrome) is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 2 of these trials.
Enrollment posture brief
Registry condition mds-myelodysplastic-syndrome
OPEN 6 | RECR 86% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)
MDS (Myelodysplastic Syndrome) lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for MDS (Myelodysplastic Syndrome) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
MDS (Myelodysplastic Syndrome) is recruiting above its size-band peers.
6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates MDS (Myelodysplastic Syndrome) research.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical MDS (Myelodysplastic Syndrome) enrolment sits around 60 participants.
Median target enrolment is 60 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
MDS (Myelodysplastic Syndrome) research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT06859424
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
National Heart, Lung, and Blood Institute (NHLBI)
NCT01174108
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT06839456
Luspatercept + Darbepoetin in MDS
Yale University
NCT07096297
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics
NCT06680752
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health
NCT05589896
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Heart, Lung, and Blood Institute (NHLBI)
NCT01866839
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on MDS (Myelodysplastic Syndrome) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on MDS (Myelodysplastic Syndrome) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this MDS (Myelodysplastic Syndrome) page
7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 MDS (Myelodysplastic Syndrome) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most MDS (Myelodysplastic Syndrome) trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MDS (Myelodysplastic Syndrome) condition card totals 7 registered trials; most-linked intervention Graft Manipulation (CD34+ Selection); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.